Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic acid for pediatric hepatitis A
IRCT20171113037429N1Phase 3Completed
- Sponsor
- Zabol University of Medical Sciences
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ursodeoxycholic acid in hepatitis A (HAV) (2 arms), sponsored by Zabol University of Medical Sciences. Primary endpoints: Alanine aminotransferase, Aspartate aminotransferase and 1 more. Started Jan 2017; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on IRCT20171113037429N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171113037429N1.